Relive the excitement of the Patriots’ path to their fourth Super Bowl Championship with “Pumped,” a special commemorative book from The Boston Globe.

EU fines drug firms over delay

AMSTERDAM — The European Commission has fined pharmaceuticals giants Johnson & Johnson and Novartis a combined $22 million for colluding to delay the entrance of a cheap generic form of a pain killer to the Dutch market.

In a statement, the commission’s antitrust chief, Joaquin Almunia, said the two companies ‘‘shockingly deprived patients in the Netherlands, including people suffering from cancer, from access to a cheaper version of this medicine.’’

Continue reading below

The commission found that after Johnson & Johnson’s patent on a patch containing the drug Fentanyl expired in 2005, it paid Novartis to delay launching a generic version.

The delay lasted 17 months, and was more profitable for both companies than competing honestly would have been.

J&J’s fine was $14.7 million, and Novartis’s was $7.6 million.

Loading comments...

Wake up with today's top stories.

Want each day's news headlines delivered fresh to your
inbox every morning? Just connect with us
in one of the following ways:
or
Please enter a valid email
BostonGlobe.com will never post anything without asking. Privacy Policy
Subscriber Log In

You have reached the limit of 5 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com